Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $10.55 in the prior trading day, Amicus Therapeutics Inc (NASDAQ: FOLD) closed at $10.33, down -2.09%. In other words, the price has decreased by -$2.09 from its previous closing price. On the day, 1.73 million shares were traded. FOLD stock price reached its highest trading level at $10.59 during the session, while it also had its lowest trading level at $10.32.
Ratios:
Our goal is to gain a better understanding of FOLD by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 2.78 whereas as Long-Term Debt/Eq ratio is at 2.73.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 19, 2023, Upgraded its rating to Overweight and sets its target price to $20 from $15 previously.
On September 09, 2022, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 01 ’24 when Campbell Bradley L sold 7,500 shares for $11.67 per share. The transaction valued at 87,496 led to the insider holds 886,654 shares of the business.
MCGLYNN MARGARET G sold 7,500 shares of FOLD for $100,500 on Mar 05 ’24. The Director now owns 59,289 shares after completing the transaction at $13.40 per share. On Mar 04 ’24, another insider, MCGLYNN MARGARET G, who serves as the Director of the company, sold 7,500 shares for $13.29 each. As a result, the insider received 99,675 and left with 59,289 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 3051306496 and an Enterprise Value of 3210161408. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.64 while its Price-to-Book (P/B) ratio in mrq is 18.93. Its current Enterprise Value per Revenue stands at 8.038 whereas that against EBITDA is -48.92.
Stock Price History:
Over the past 52 weeks, FOLD has reached a high of $14.57, while it has fallen to a 52-week low of $9.70. The 50-Day Moving Average of the stock is -16.04%, while the 200-Day Moving Average is calculated to be -15.81%.
Shares Statistics:
The stock has traded on average 3.04M shares per day over the past 3-months and 2304720 shares per day over the last 10 days, according to various share statistics. A total of 293.59M shares are outstanding, with a floating share count of 286.56M. Insiders hold about 2.99% of the company’s shares, while institutions hold 106.64% stake in the company. Shares short for FOLD as of 1711584000 were 32489231 with a Short Ratio of 10.70, compared to 1709164800 on 30911817. Therefore, it implies a Short% of Shares Outstanding of 32489231 and a Short% of Float of 11.05.
Earnings Estimates
Amicus Therapeutics Inc (FOLD) is presently subject to a detailed evaluation by Barrick Gold Corporation analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $73.20, with high estimates of $10.33 and low estimates of $25.25.
EPS for the following year is $ETF, with Stocks analysts recommending between $Stocks and $Stocks.
